Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors
NOTE: This trial is currently enrolling into the extension arm.
The purpose of this phase I trial is to evaluate the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors.
Biomarker testing to determine if patient is eligible for the trial must be completed prior to screening for the trial and confirmed at screening.
Study ID: OSU-09138
Trial Phase: Phase I
Trial Sponsor: Ohio State University
Therapies Used in This Trial: HER-2 vaccine